BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

14485

530199

THEMISMED

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

THEMIS MEDICARE LTD. performance

Today’s low

Today’s high

₹ 133.56 ₹ 140.50
₹ 138.66

52 week low

52 week high

₹ 115.00 ₹ 317.00
₹ 138.66

Open Price

₹ 138.94

Prev. Close

₹ 137.82

Volume (Shares)

147010.00

Total traded value

₹ 203.84

Upper Circuit

₹ 165.38

Lower Circuit

₹ 110.25

info

THEMIS MEDICARE LTD. Share Price Update

As of the latest trading session, THEMIS MEDICARE LTD. share price is currently at ₹ 138, which is up by ₹ 0.17 from its previous closing. Today, the stock has fluctuated between ₹ 133.56 and ₹ 140.50. Over the past year, THEMIS MEDICARE LTD. has achieved a return of -36.98 %. In the last month alone, the return has been 4.44 %. Read More...

THEMIS MEDICARE LTD. fundamentals


  • Market cap (Cr)

    1,276.20

  • P/E Ratio (TTM)

    53.73

  • Beta

    1.95

  • Book Value / share

    31.17

  • Return on equity

    9.59%

  • EPS (TTM)

    2.60

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -7.74

info icon alternate text
  • Market cap (Cr)

    1,267.90

  • P/E Ratio (TTM)

    53.73

  • Beta

    1.89

  • Book Value / share

    31.17

  • Return on equity

    9.59%

  • EPS (TTM)

    2.60

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -7.74

info icon alternate text

THEMIS MEDICARE LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 71.70
Operating Expense 82.46
Net Profit -7.74
Net Profit Margin (%) -10.79
Earnings Per Share (EPS) -0.84
EBITDA -4.23
Effective Tax Rate (%) 15.85
Particulars DEC 2024 (Values in Cr)
Revenue 93.81
Operating Expense 90.61
Net Profit 3.08
Net Profit Margin (%) 3.28
Earnings Per Share (EPS) 0.33
EBITDA 9.55
Effective Tax Rate (%) 27.01
Particulars SEP 2024 (Values in Cr)
Revenue 117.01
Operating Expense 104.77
Net Profit 9.87
Net Profit Margin (%) 8.43
Earnings Per Share (EPS) 1.08
EBITDA 18.25
Effective Tax Rate (%) 26.17
Particulars JUN 2024 (Values in Cr)
Revenue 106.08
Operating Expense 79.28
Net Profit 18.71
Net Profit Margin (%) 17.63
Earnings Per Share (EPS) 2.03
EBITDA 29.95
Effective Tax Rate (%) 26.18
Particulars MAR 2024 (Values in Cr)
Revenue 75.52
Operating Expense 69.69
Net Profit 3.09
Net Profit Margin (%) 4.09
Earnings Per Share (EPS) 0.34
EBITDA 9.33
Effective Tax Rate (%) 37.08
Particulars MAR 2025 (Values in Cr)
Revenue 405.51
Operating Expense 376.42
Net Profit 23.92
Net Profit Margin (%) 5.89
Earnings Per Share (EPS) 2.60
EBITDA 53.73
Effective Tax Rate (%) 29.14
Particulars MAR 2024 (Values in Cr)
Revenue 381.76
Operating Expense 351.85
Net Profit 24.75
Net Profit Margin (%) 6.48
Earnings Per Share (EPS) 2.69
EBITDA 56.30
Effective Tax Rate (%) 28.61
Particulars MAR 2023 (Values in Cr)
Revenue 354.32
Operating Expense 306.92
Net Profit 43.29
Net Profit Margin (%) 12.21
Earnings Per Share (EPS) 47.05
EBITDA 78.96
Effective Tax Rate (%) 26.49
Particulars MAR 2022 (Values in Cr)
Revenue 394.61
Operating Expense 317.21
Net Profit 61.56
Net Profit Margin (%) 15.60
Earnings Per Share (EPS) 66.91
EBITDA 102.19
Effective Tax Rate (%) 26.66
Particulars MAR 2021 (Values in Cr)
Revenue 230.67
Operating Expense 202.04
Net Profit 26.62
Net Profit Margin (%) 11.54
Earnings Per Share (EPS) 28.97
EBITDA 53.51
Effective Tax Rate (%) 17.45
Particulars MAR 2024 (Values in Cr)
Book Value / Share 37.41
ROE % 13.39
ROCE % 14.99
Total Debt to Total Equity 0.29
EBITDA Margin 19.66
Particulars MAR 2023 (Values in Cr)
Book Value / Share 332.15
ROE % 20.36
ROCE % 22.45
Total Debt to Total Equity 0.31
EBITDA Margin 26.13
Particulars MAR 2022 (Values in Cr)
Book Value / Share 275.34
ROE % 33.33
ROCE % 34.44
Total Debt to Total Equity 0.38
EBITDA Margin 28.77
Particulars MAR 2021 (Values in Cr)
Book Value / Share 200.18
ROE % 21.51
ROCE % 20.82
Total Debt to Total Equity 0.56
EBITDA Margin 27.13
Particulars MAR 2020 (Values in Cr)
Book Value / Share 161.14
ROE % 18.30
ROCE % 17.57
Total Debt to Total Equity 0.67
EBITDA Margin 23.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 29.11
ROE % 9.59
ROCE % 12.51
Total Debt to Total Equity 0.36
EBITDA Margin 14.74
Particulars MAR 2023 (Values in Cr)
Book Value / Share 269.54
ROE % 18.93
ROCE % 21.75
Total Debt to Total Equity 0.38
EBITDA Margin 22.28
Particulars MAR 2022 (Values in Cr)
Book Value / Share 227.50
ROE % 34.15
ROCE % 35.15
Total Debt to Total Equity 0.46
EBITDA Margin 25.90
Particulars MAR 2021 (Values in Cr)
Book Value / Share 164.59
ROE % 19.32
ROCE % 19.43
Total Debt to Total Equity 0.68
EBITDA Margin 23.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 135.33
ROE % 13.70
ROCE % 14.92
Total Debt to Total Equity 0.78
EBITDA Margin 19.42
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.29
Total Assets 566.41
Total Liabilities 566.41
Total Equity 377.66
Share Outstanding 92040120
Price to Book Ratio 7.52
Return on Assets (%) 7.68
Return on Capital (%) 9.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 18.88
Total Assets 513.95
Total Liabilities 513.95
Total Equity 339.44
Share Outstanding 9202770
Price to Book Ratio 4.33
Return on Assets (%) 11.07
Return on Capital (%) 13.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 26.49
Total Assets 427.78
Total Liabilities 427.78
Total Equity 287.48
Share Outstanding 9200270
Price to Book Ratio 4.10
Return on Assets (%) 17.03
Return on Capital (%) 19.91
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 24.63
Total Assets 371.14
Total Liabilities 371.14
Total Equity 218.50
Share Outstanding 9188454
Price to Book Ratio 1.70
Return on Assets (%) 9.61
Return on Capital (%) 11.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.29
Total Assets 349.91
Total Liabilities 349.91
Total Equity 183.02
Share Outstanding 9187992
Price to Book Ratio 1.77
Return on Assets (%) 7.08
Return on Capital (%) 9.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.20
Total Assets 489.96
Total Liabilities 489.96
Total Equity 301.27
Share Outstanding 92040120
Price to Book Ratio 7.52
Return on Assets (%) 5.05
Return on Capital (%) 6.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 18.85
Total Assets 456.28
Total Liabilities 456.28
Total Equity 281.82
Share Outstanding 9202770
Price to Book Ratio 4.33
Return on Assets (%) 9.48
Return on Capital (%) 11.58
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 26.48
Total Assets 383.73
Total Liabilities 383.73
Total Equity 243.48
Share Outstanding 9200270
Price to Book Ratio 4.10
Return on Assets (%) 16.04
Return on Capital (%) 19.12
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 24.62
Total Assets 338.40
Total Liabilities 338.40
Total Equity 185.80
Share Outstanding 9188454
Price to Book Ratio 1.70
Return on Assets (%) 7.86
Return on Capital (%) 9.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.28
Total Assets 326.17
Total Liabilities 326.17
Total Equity 159.31
Share Outstanding 9187992
Price to Book Ratio 1.77
Return on Assets (%) 4.87
Return on Capital (%) 6.42
Particulars MAR 2024 (Values in Cr)
Net Income 53.44
Cash from Operations 31.04
Cash from Investing -15.94
Cash from Financing -8.77
Net change in Cash -2.62
Free Cash Flow 49.46
Particulars MAR 2023 (Values in Cr)
Net Income 72.51
Cash from Operations 32.24
Cash from Investing -23.96
Cash from Financing 0.13
Net change in Cash -7.73
Free Cash Flow 60.99
Particulars MAR 2022 (Values in Cr)
Net Income 95.26
Cash from Operations 52.46
Cash from Investing -15.58
Cash from Financing -17.54
Net change in Cash 1.26
Free Cash Flow 73.09
Particulars MAR 2021 (Values in Cr)
Net Income 41.33
Cash from Operations 56.89
Cash from Investing -15.65
Cash from Financing -25.64
Net change in Cash 15.67
Free Cash Flow 74.93
Particulars MAR 2020 (Values in Cr)
Net Income 26.87
Cash from Operations 0.57
Cash from Investing -5.46
Cash from Financing 6.72
Net change in Cash 1.58
Free Cash Flow 6.37
Particulars MAR 2024 (Values in Cr)
Net Income 34.66
Cash from Operations 31.00
Cash from Investing -15.95
Cash from Financing -8.77
Net change in Cash -2.68
Free Cash Flow 49.41
Particulars MAR 2023 (Values in Cr)
Net Income 58.90
Cash from Operations 32.22
Cash from Investing -23.96
Cash from Financing 0.13
Net change in Cash -7.75
Free Cash Flow 60.97
Particulars MAR 2022 (Values in Cr)
Net Income 83.93
Cash from Operations 52.46
Cash from Investing -15.58
Cash from Financing -17.54
Net change in Cash 1.26
Free Cash Flow 73.09
Particulars MAR 2021 (Values in Cr)
Net Income 32.24
Cash from Operations 56.89
Cash from Investing -15.65
Cash from Financing -25.64
Net change in Cash 15.67
Free Cash Flow 74.93
Particulars MAR 2020 (Values in Cr)
Net Income 18.00
Cash from Operations 0.57
Cash from Investing -5.45
Cash from Financing 6.72
Net change in Cash 1.59
Free Cash Flow 6.37
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

THEMIS MEDICARE LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
138.66 0.60 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 141.50
  • 26 Days 140.20
  • 10 Days 141.00
  • 50 Days 144.90
  • 12 Days 140.80
  • 100 Days 165.00
  • 20 Days 140.30
  • 200 Days 190.00
139.63 PIVOT

First Support

132.84

First Resistance

144.62

Second Support

127.85

Second Resistance

151.41

Third Support

121.06

Third Resistance

156.40

RSI

47.75

ADX

30.72

MACD

0.62

Williams % R

-76.30

Commodity Channel Index (CCI)

-40.34

Date

2025-06-13

Week

105343.00

Same Day

100171.00

Month

83205.00

1 Year

1.96

3 Year

1.31

Over 1 Month

4.44%

down

Over 1 Year

-36.98%

down

Over 3 Months

-6.26%

down

Over 3 Years

20.89%

down

Over 6 Months

-52.07%

down

Over 5 Years

34.85%

down

THEMIS MEDICARE LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
32.69%
Promoter Holdings
67.14%
FII
0.13%
DII
0.01%
Promoter Shares(Pledge Percentage)
2.43%
Name Shares Category
Vividhmargi Investments Pvt 1.452842E7 (15.78%) Shareholding of Promoter and Promoter Group
Gedeon Richter Investment Management Ltd. 8843080.0 (9.61%) Shareholding of Promoter and Promoter Group
Dinesh Shantilal Patel 8720570.0 (9.47%) Shareholding of Promoter and Promoter Group
Vividh Distributors Pvt Ltd 7161000.0 (7.78%) Shareholding of Promoter and Promoter Group
Jayshree D Patel 6676640.0 (7.25%) Shareholding of Promoter and Promoter Group
Sachin Dinesh Patel 5516550.0 (5.99%) Shareholding of Promoter and Promoter Group
Anuj Anantrai Sheth 4300000.0 (4.67%) Public Shareholding
Reena S Patel 3714910.0 (4.04%) Shareholding of Promoter and Promoter Group
Themis Distributors Private Limited 2740040.0 (2.98%) Shareholding of Promoter and Promoter Group
Zafar Ahmadullah 1945964.0 (2.11%) Public Shareholding
Za Capital Services India Private Ltd 1411893.0 (1.53%) Public Shareholding
Nysha Rupen Choksi 1176890.0 (1.28%) Shareholding of Promoter and Promoter Group
Anay Rupen Choksi 1176890.0 (1.28%) Shareholding of Promoter and Promoter Group
Dinesh S Patel Huf 989000.0 (1.07%) Shareholding of Promoter and Promoter Group
Shantilal Dahyabhai Patel (huf) 558000.0 (0.61%) Shareholding of Promoter and Promoter Group
Rupen Ashwin Choksi 2000.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

THEMIS MEDICARE LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Sep 2023 5.0 Final 02 Sep 2023 Equity shares
08 Sep 2022 5.0 Final 12 Sep 2022 Equity shares
08 Sep 2021 4.3 Final 11 Sep 2021 Equity shares
17 Sep 2020 1.75 Final 21 Sep 2020 Equity shares
20 Jul 2011 3.0 Final 22 Jul 2011 Equity shares
16 Jun 2010 3.0 Final 18 Jun 2010 Equity shares
01 Aug 2008 2.5 Final 05 Aug 2008 Equity shares
14 Sep 2007 2.0 Final 18 Sep 2007 Equity shares
03 Aug 2005 0.0 Final 05 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
10 Oct 2023 10.0 1.0 10 Oct 2023
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Jul 2024 0.5 Final 15 Jul 2024 Equity shares
01 Sep 2023 5.0 Final 02 Sep 2023 Equity shares
08 Sep 2022 5.0 Final 12 Sep 2022 Equity shares
08 Sep 2021 4.3 Final 11 Sep 2021 Equity shares
17 Sep 2020 1.75 Final 21 Sep 2020 Equity shares
20 Jul 2011 3.0 Final 22 Jul 2011 Equity shares
16 Jun 2010 3.0 Final 18 Jun 2010 Equity shares
01 Aug 2008 2.5 Final 05 Aug 2008 Equity shares
14 Sep 2007 2.0 Final 18 Sep 2007 Equity shares
03 Aug 2005 0.0 Final 05 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
10 Oct 2023 10.0 1.0 10 Oct 2023

THEMIS MEDICARE LTD. Share Price

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969. The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993. Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.

In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments.

Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary.

The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.

The Company introduced products like Cardiac and Muscular Relaxant during the year 2001-02. A wholly owned subsidiary of the Company, Themis Medicare Singapore Pte. Ltd., formed on 22nd May, 2002 in Singapore became operational during the year 2002-03.

M/s. Artemis Biotech Ltd., a Group Company was merged with Themis Medicare Ltd. (the Parent Company) with effect from 1st April 2003. The Joint Venture Company, 'Richter Themis Medicare (India) Pvt. Ltd.' started manufacturing activities at its EOU unit at Vapi effective from March, 2006. The Company started operations of its new Injection Plant at Haridwar for tablets and gel formulation production in 2006-07. 'Themiseal', the Company's unique haemostatic and anti-microbial product was launched in the UK, Greece, Cyprus, Jordan, Romania and Indonesia.

During the year 2010-11, a Private Ltd Subsidiary Company in the name and style of Themis Lifestyle Pvt. Ltd was incorporated on 3rd November, 2010 and another Public Ltd Subsidiary Company in the name and style of Artemis Biotech Ltd. was incorporated on 14th January, 2011.

During FY 2016-17, HID-PUL KFT (Hungary), a Wholly Owned Subsidiary of the Company, ceased to be a subsidiary of the Company. 'Carpo Medical Limited' was incorporated as a Joint Venture Company in the United Kingdom in 2016-17.

The Company launched a new product - Lenzetto Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms in 2023. As part of a strategy to concentrate on both the API and the Hospital Business, the Company demerged the API segment of the Company, including both the API production facilities, to a 100% owned subsidiary company, Themis Lifestyle Private Limited through slump sale in 2023.

Parent organization Themis
NSE symbol THEMISMED
Founded 1969
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Themis Medicare Ltd?

Answer Field

Themis Medicare Ltd share price is for NSE ₹ 138.00 & for BSE ₹ 139.50 as on Jun 16 2025 03:29 PM.

What is the Market Cap of Themis Medicare Ltd Share?

Answer Field

The market cap of Themis Medicare Ltd for NSE ₹ 1,270.15 & for BSE ₹ 1,283.96 as on Jun 16 2025 03:29 PM.

What is the 52 Week High and Low of Themis Medicare Ltd?

Answer Field

The 52 Week High and Low of Themis Medicare Ltd for NSE is ₹ 317.00 and ₹ 115.00 and for BSE is ₹ 313.65 and ₹ 115.05.

What is 1 year return for Themis Medicare Ltd?

Answer Field

The 1 year returns on the stock has been -36.98%.

What is the P/E Ratio of Themis Medicare Ltd Share?

Answer Field

As on Jun 16 2025 03:29 PM the price-to-earnings (PE) ratio for Themis Medicare Ltd share is 53.73.

What is the PB ratio of Themis Medicare Ltd Share?

Answer Field

As on Jun 16 2025 03:29 PM, the price-to-book (PB) ratio for Themis Medicare Ltd share is 31.17.

How to Buy Themis Medicare Ltd Share?

Answer Field

You can trade in Themis Medicare Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Themis Medicare Ltd Share on Bajaj Broking App?

Answer Field

To buy Themis Medicare Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Themis Medicare Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|